AzTrials
AzTrials

OsteoarthritisTWEAKNCT02628795

Overcoming TWEAK Signaling to Restore Muscle and Mobility After Joint Replacement

A study testing PRT + FM in people with Osteoarthritis, run by University of Alabama at Birmingham at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This single-blind, randomized, controlled trial is designed to test the effect of an intensive, 16 week exercise rehabilitation program (progressive resistance training + functional mobility training) vs. Read more about this study

Who is it for?
Ages 40 to 80 years
Conditions the study is for
Osteoarthritis
What is being tested?
PRT + FM
Could I receive a placebo?
No, everyone receives an active treatment
How many people
80 participants
Where
1 siteUnited States
Study dates
Oct 2015to 28 Feb 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Between the ages 40 and 80 y.
  • Scheduled to undergo elective total hip or knee replacement specifically for the surgical indication of end-stage osteoarthritis.
  • First-time hip or knee replacement.
  • Capable of providing informed consent (cognitively intact if consenting to surgery).

Who cannot join

  • Any surgical indication other than first-time total joint replacement specifically for end-stage osteoarthritis.
  • Bilateral knee/ hip replacement
  • History of alcoholism or liver disease.
  • Any history of hypo- or hyper-coagulation disorders including subjects taking Coumadin.
  • Any individual with end-stage disease and/or a life expectancy less than one year.
  • Pregnancy.
Show all 16Show fewer
  • Lactating Women.
  • Neurological, musculoskeletal, or other disorder that would preclude them from completing the exercise training intervention and all performance tests.
  • Uncontrolled hypertension, unstable or exercise-induced angina pectoris or myocardial ischemia, congestive heart failure.
  • Uncontrolled diabetes mellitus.
  • Any other condition or events considered exclusionary by the PIs and/or physician Co-Is.
  • Lidocaine allergy (1% lidocaine is the local anesthetic used during the muscle biopsy procedure).
  • Phenylketonuria (phenylalanine tracer for metabolic studies).
  • Currently receiving androgen (e.g., testosterone) or anabolic (e.g., growth hormone (GH), insulin-like growth factor-I (IGF-I)) therapy.
  • Body mass index ≥ 35.
  • History of lower body progressive resistance training within the past year.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • UAB Center for Exercise Medicine

    Birmingham, Alabama, 35205

Other trials in United States

About this study

This single-blind, randomized, controlled trial is designed to test the effect of an intensive, 16 week exercise rehabilitation program (progressive resistance training + functional mobility training) vs. usual care on restoration of muscle mass and mobility after total hip (THA) or knee (TKA) arthroplasty in men and women with end-stage osteoarthritis. The molecular basis underlying the trial is the presence of significant muscle inflammation susceptibility in many of these individuals, and the expectation that the more intensive intervention will overcome this inflammatory burden to facilitate recovery.

Read the detailed description

While elective total hip (THA) and knee (TKA) arthroplasty relieve pain and improve mobility function for thousands with end-stage osteoarthritis (OA), up to 35% endure persistent muscle atrophy and mobility limitations for several years that impact life quality, increase morbidity, and burden the healthcare system. Given that THA/TKA volumes are increasing exponentially with >1.1 million in the US annually, refractory mobility impairment is a major public health problem. Together, the available data raise two important knowledge gaps in THA/TKA rehabilitation: (i) poorly understood factors that limit responsiveness of a large number of patients to current usual care; and (ii) the absence of rehabilitation programs proven to overcome these limitations. The proposed project is designed to fill these gaps. The investigators' fundamental tenet is that restoration of mobility function following THA/TKA requires: (i) regeneration of surgically damaged muscle; and (ii) regrowth of muscles that have atrophied over years of OA and limited usage. The investigators suggest a major cause of muscle regeneration impairment in some individuals is what the investigators identified as muscle inflammation susceptibility (MuIS) - hyperactive inflammatory signaling in muscle of MuIS(+) individuals despite no systemic inflammation - which also manifests in isolated primary satellite cells and inhibits myogenesis in vitro, indicative of a true cellular phenotype beyond the niche. The investigators' preliminary findings in THA/TKA patients strongly suggest the tumor necrosis factor-like weak inducer of apoptosis (TWEAK) signaling pathway may be central to MuIS and impaired THA/TKA recovery, as high perioperative muscle TWEAK signaling in the ipsilateral thigh was the most sensitive indicator of impaired muscle protein synthesis and failed strength recovery after 8 wk of usual care. Progressive resistance exercise training (PRT) is a putative anabolic intervention that the investigators find consistently increases muscle mass to meet healthy standards in atrophied and mobility-impaired adults, by activating muscle protein synthesis and the myogenic activity of muscle satellite cells. Together, these findings raise the central hypothesis that PRT plus adjunctive functional mobility training (PRT+FM) after THA/TKA will more effectively restore muscle mass and mobility function to healthy standards than usual care and, because MuIS(+) are predicted to suffer failed muscle recovery and persistent dismobility under usual care, the impact of PRT+FM will be greatest in MuIS(+). The investigators will thoroughly test this hypothesis in a randomized controlled trial of 88 THA/TKA patients with the following aims. Aim 1: To determine the effects of 16 wk of PRT+FM vs. usual care after elective THA/TKA on muscle mass, performance, and mobility function. Aim 2: To determine whether MuIS status modifies the effects of PRT+FM or usual care after THA/TKA. Cellular and molecular mechanisms of muscle mass regulation will be studied in detail. Aim 3. To determine the long-term impact of 16 wk PRT+FM by re-assessing outcomes at 6 mo and 1 y. The investigators fully expect the novel findings to lead a paradigm shift in THA/TKA rehabilitation that will have a profound impact on a growing segment of the population.

Conditions
Osteoarthritis
Being tested
PRT + FM, Usual Care
Keywords
total hip arthroplasty, total knee arthroplasty
Medical subject headings
Osteoarthritis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PRT + FMBehavioural

    Supervised progressive resistance training + functional mobility training (PRT+FM) 3 days per week for 16 weeks post-surgery.

  • Usual CareOther

    Post-surgical usual care activities including any prescribed physical therapy

Study groups in NCT02628795
Study groupRoleWhat they receive
PRT + FMExperimentalProgressive resistance training + functional mobility training 3 d/wk x 16 wk
Receives: Behavioral: PRT + FM; Other: Usual Care
Usual CareActive comparatorPost-surgical usual care including physical therapy
Receives: Other: Usual Care

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in unilateral (surgical) thigh muscle mass (unit of measure = grams)

    Primary muscle mass outcome of Aim 1

    Measured: Pre-surgery to 16 weeks post-surgery

  2. Change in unilateral (surgical) knee extension power (unit of measure = watts)

    Primary functional outcome of Aim 1

    Measured: Pre-surgery to 16 weeks post-surgery

  3. Change in short physical performance battery (SPPB) (unit of measure = score)

    Primary outcome of Aim 3

    Measured: From 16 weeks post-surgery to 26 and 52 weeks post-surgery

  4. Muscle inflammation susceptibility (MuIS) status (unit of measure = relative value)

    Primary outcome of Aim 2: Muscle inflammation susceptibility (MuIS) defined by TWEAK receptor gene expression

    Measured: At the time of surgery

Secondary outcomes (3)
  1. Change in muscle fiber size (unit of measure = micrometers squared)

    Measured: From the time of surgery to 16 weeks post-surgery

  2. Change in unilateral (surgical) knee extension isometric strength (unit of measure = Newton-meters)

    Measured: Pre-surgery to 16 weeks post-surgery

  3. Change in maximum 10-meter gait speed (unit of measure = meters per second)

    Measured: Pre-surgery to 16 weeks post-surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Dec 2015 (estimated)
  2. Study startOct 2015
  3. Primary completion1 Sep 2020
  4. Study completion28 Feb 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Investigator
Enrolment
80 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02628795
Sponsor's protocol ID
R01HD084124
Other IDs
R01HD084124
Acronym
TWEAK
Status last verified
Jul 2021
First submitted
5 Aug 2015
Last updated
7 Jul 2021
Results posted
No
Data monitoring committee
Yes
Individual data sharing
Undecided: Data might be provided on written request in aggregate form.

Questions about this trial

What is this clinical trial studying?

A study testing PRT + FM in people with Osteoarthritis, run by University of Alabama at Birmingham at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Jul 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in unilateral (surgical) thigh muscle mass (unit of measure = grams) (time frame: Pre-surgery to 16 weeks post-surgery). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jul 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in